title: [A dyad approach to the treatment of attention deficit hyperactivity disorder].
abstract: OBJECTIVE
  To study anxiety in adolescents with attention deficit hyperactivity disorder (ADHD) and their mothers and to evaluate the efficacy of a dyad approach (simultaneous treatment of the mother and the child) to ADHD treatment.
  
  
  METHODS
  Thirty-four adolescents, aged 12-15 years, with ADHD and their mothers were studied. All participants of the study received anxiolytic treatment: children were treated with noophen (500 mg per day 45 days) and their mothers received adaptol (1500 mg per day 45 days). In the comparison group with the same clinical/psychological characteristics, anxiolytic therapy with noophen was used only in adolescents.
  
  
  RESULTS
  Symptoms of anxiety were found in 61.7% of adolescents with ADHD and in 79.4% of the mothers. After the dyad therapy, an improvement was noted in 73.5% of adolescents and 69.7% of the mothers. There was an improvement in 63.3% of patients in the comparison group.
  
  
  CONCLUSIONS
  The results demonstrate the high efficacy of the dyad approach in treatment of ADHD with comorbid anxiety disorders.
authors.affiliation: N. Bekhtereva Human Brain Research Institute, Russian Academy of Science, St. Petersburg, Russia.
authors.forename: L S
authors.initials: LS
authors.lastname: Chutko
authors.affiliation: N. Bekhtereva Human Brain Research Institute, Russian Academy of Science, St. Petersburg, Russia.
authors.forename: S Yu
authors.initials: SY
authors.lastname: Surushkina
authors.affiliation: N. Bekhtereva Human Brain Research Institute, Russian Academy of Science, St. Petersburg, Russia.
authors.forename: T I
authors.initials: TI
authors.lastname: Anisimova
mesh_terms: D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000453:epidemiology; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology; D001736:Biureas / Q000627:therapeutic use*; D002648:Child; D015897:Comorbidity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009035:Mothers / Q000523:psychology*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D014151:Anti-Anxiety Agents; D001736:Biureas; C015979:mebikar; D005680:gamma-Aminobutyric Acid; C008842:4-amino-3-phenylbutyric acid